Spectrum Therapeutics has secured licences for the first UK medicinal cannabis distribution centre.
Spectrum Therapeutics UK received licences from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Home Office to store and distribute cannabis-based medicinal products (CBMPs). The first-of-its-kind facility based in the UK, will aim to reduce prescription delivery time. The licence also allows the company to import CBMPs to the UK directly from Spectrum’s European and global network, optimising its supply chain and reducing overheads, without need for third-party suppliers.
Cosmo Feilding Mellen, Managing Director, Spectrum Therapeutics UK, said: “Medicinal cannabis has been available in the UK as an unlicenced special for nearly twelve months, and in that time, industry has faced the challenge of establishing a new UK infrastructure to meet the needs of patients.
“We are delighted to have been granted licences from both the MHRA and Home Office in order to provide a solution to one of the most significant barriers for access in the UK. We are actively working with regulators to find the best way to ensure we can deliver continuous treatment to patients within the framework that exists.”
Spectrum Therapeutics UK passed a rigorous preliminary inspection from the MHRA to receive a licence. Going forward, the company will be actively engaged in quality and process improvements relating to medicinal cannabis through regular inspections. The company will continue to work closely with the MHRA and the Home Office to maintain the agreed terms, ensuring that CBMPs can be stored at volume in the UK under the highest standards of practice.